Inquiry Basket
Loading ......
In the landscape of targeted cancer therapy, ramucirumab has emerged as a cornerstone treatment for advanced solid tumors, including gastric adenocarcinoma, metastatic colorectal cancer, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC). As a human IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2), ramucirumab inhibits tumor angiogenesis by blocking ligand binding (VEGF-A, VEGF-C, VEGF-D), thereby starving tumors of nutrient supply. However, like all biotherapeutics, its efficacy can be compromised by the development of anti-drug antibodies (ADAs), which may neutralize the drug, accelerate clearance, or trigger adverse reactions. Accurate ADA detection is therefore critical for optimizing patient outcomes, making the selection of a reliable ELISA kit paramount for clinical laboratories and researchers.
Figure 1. Ramucirumab Anti-Drug Antibody (ADA) Detection.
Remdesizumab is a fully humanized IgG1 monoclonal antibody that specifically binds to vascular endothelial growth factor receptor-2 (VEGFR-2). VEGF is a key mediator of tumor angiogenesis and is overexpressed in many solid tumors, making it a major target for anti-tumor angiogenesis. The VEGF growth factor family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor (PLGF), among which VEGF-A is one of the most critical stimulators of tumor angiogenesis. VEGF-A can bind to three different tyrosine kinase receptors, VEGFR-1, VEGFR-2, and VEGFR-3, with VEGFR-2 being the most critical. Ramolumab inhibits the activation of VEGFR-2 by blocking its binding to VEGF-A, VEGF-C, and VEGF-D, thereby suppressing tumor angiogenesis by inhibiting endothelial growth, migration, and survival, and exerting anti-tumor effects. At present, it has been applied in second-line treatment of various malignant tumors, including gastric cancer, non-small cell lung cancer, colorectal cancer, hepatocellular carcinoma, etc.
Figure 2. Structure of VEGFR.
Technology Platform
Sample Type Compatibility
Sensitivity Profile
Kit Features
Introduction
Key Features of the Ideal ELISA Kit for Ramucirumab ADA Detection
The ELISA Principle of Ramucirumab ADA detection
Key Criteria for Selecting Reagent Kits
| Parameter | Details |
| Product name | Anti-Ramucirumab ELISA Kit |
| Precision | Intra-assay and inter-assay CVs<30% |
| Species Reactivity | Human |
| Contents of Kit | 1. Microtiter Plate: 1 × 12 × 8 Break apart strips. Microtiter plate with 12 rows each of 8 wells coated with ramucirumab. 2. Controls 1.0 mL (negative); 1.0 mL (positive) Ready to use. Contains human serum and stabilizer,<0.1% NaN3. 3. Assay Buffer 1 × 50 Ml Ready to use. Blue coloured. Contains proteins,<0.1% NaN3. 4. Conjugate 1 × 12 Ml Horse radish peroxidase conjugated probe. Ready to use. Red coloured. Contains HRP conjugated probe, stabilizer and preservatives. 5. Substrate 1 × 12 Ml TMB substrate solution Ready to use. Contains 3,3´,5,5´-Tetramethylbenzidine (TMB). 6. Stop Buffer 1 × 12 Ml TMB stop solution. Ready to use. 1N HCl. 7. Wash Buffer 1 × 50 Ml Prepared concentrated (20×) and should be diluted with the dilution rate given in the "Reagent Preparation" before the test. Contains buffer with tween 20. 8. Foil 2 × 1 Adhesive Foil. For covering microtiter plate during incubation. |
Fast turnaround time
Most test kits can detect results within 2-3 hours, which is faster than virus culture and on par with RIDT. This allows clinicians to make clinical decisions in a timely manner (eg. start antiviral therapy).
Quantitative Results
In contrast to qualitative RIDT, ELISA provides numerical information on antigen/antibody levels. It can be used to assess the viral load (antigen levels) and quantify the immune status (antibody titers).
Cost Effectiveness
ELISA kits are less expensive than RT-PCR, especially for high-throughput detection. It requires minimal equipment (microplate readers) and can be performed by trained technicians.
In conclusion, the selection of the best ELISA kit for ramucirumab ADA detection is not a one-size-fits-all process. It requires a careful evaluation of the kit's analytical performance, its suitability for the specific drug and patient population, and the manufacturer's commitment to quality and validation. By prioritizing kits with high sensitivity, specificity, and drug tolerance, and by confirming their robustness and regulatory compliance, researchers and clinicians can ensure the integrity of their data and, ultimately, the safety and well-being of their patients.
Loading ......
